international journal of pharmaceutical research impact factor

Welcome to Global Research online:

Our philosophy is to map new frontiers in emerging and developing technology areas in research, industry and governance, and to link with centers of excellence worldwide to provide authoritative coverage and references in focused and specialist fields.

We enforced to encourage the global research teams and personnel who engaged their life with new achievements for the better future of human kind.

We are publishing non-profit peer-reviewed International Journals of Pharmaceutical field.

We started with a Mission to encourage contribution to Research in Sciences & Technology for achieving better future lives for all. We serve Science & Mankind at the highest levels of Professional Ethical Conduct.

Presently we are handling the emerging Pharmaceutical field. The title of our International Pharma Journal is:

International Journal of Pharmaceutical Sciences Review and Research (Int J Pharm Sci Rev Res, CODEN: IJPSRR) (ISSN: 0976-044X)

International Journal of Pharmaceutical Sciences Review and Research (Int J Pharm Sci Rev Res) is an open access, bi-monthly published, peer-reviewed, international online journal.

The journal will cover topics related to Pharmaceutical Sciences (Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Novel Drug Delivery, Pharmaceutical/Medicinal Chemistry, formulation technology, pharmaceutical product development, nutraceutical product development, cosmetic product development, Pharmacognosy and Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest, quality assurance, herbal technology, regulatory affairs, Pharmaceutical marketing, Biological sciences, Botany, Zoology, Biochemistry etc.).

Our International Journal of Pharmaceutical Sciences Review and Research (IJPSRR) achieved a good index copernicus value in short span of time amongst International community with great impact.

Elsevier-Scopus SCImago Impact factor 2016 = 0.65

Scopus SCImago Journal Rank (SJR) 2018: 0.18

Index copernicus value: ICV 2016: 92.89, ICV 2017: 71.72

SJIF 2018 = 6.857 (Scientific Journal Impact Factor Value for 2018)

Our journal was indexed in the following:

Crossref DOI

Index Copernicus International Ltd, Poland

Gale and EMBASE (Elsevier Products, currently indexed)

SCOPUS (Elsevier Product, indexed up to 2016)

Directory of Open Access Journal (DOAJ), Sweden

Urlich's Periodicals Directory, Proquest, UK

EBSCO Publishing Inc (Academic Search Complete), USA

Open-J-Gate, India

NewJour-Georgetown University Library, USA

The Open Access Digital Library, USA

Lenide Journals

Dayang journal system, Korea

Science central, USA

San Jose State University Library, USA

Pharma Trendz International

Google Scholar

Pharmpedia, Canada

VIKAS PSOAR (Pharmaceutical Sciences Open Access Resources)

Chemical Abstracts Service (CAS), USA

SOCOLAR, China

Indian Science

Research Bible - Journal Seeker

Rubriq Beta

Academia, Refertus, eannu, The Journal database (TJDB) and in TutorGig

Further, in the positive opinion by:

Thomson Reuters, USA

Journal Impact Factor, Please read the following:

• Abstracting and Indexing
• Editorial Board

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES

The International Journal of Pharmaceutical Research and Allied Sciences (IJPRAS) is an international double-blind peer-reviewed open access journal. The quarterly publishing journal is multi-disciplinary pharmaceutical & scientific journal that serves scientific information, studies, and scientific outcomes of various international pharmaceutical & scientific industries, institutes and forums. 

The journal particularly aims to foster the dissemination of scientific information by publishing manuscripts related to current Pharmaceutical as well as allied sciences fields. It publishes full research papers presenting original, high quality research, critical review articles providing comprehensive analysis of research & development within a defined area. The journal provides an intellectual platform for discussion and dissemination of new ideas and latest research in pharmaceutical and allied science.

Aim and Scope The aim of our journal is publishing articles in the developing field of pharmaceutical research and allied sciences. We publish articles that enrich the practice of pharmaceutical and allied sciences marketing while simultaneously making significant contributions to the theoretical advancement of the discipline. All articles appearing in the journal are peer reviewed to ensure academic rigor and practical relevance.

Applying the research concept in the pharmaceutical and allied sciences sectors has recently caught the attention of scholars and practitioners alike. However, research concept practice as applied to these sectors remains relatively under-explored. The purpose of this new journal is to bridge this gap, and to advance our theoretical and empirical understanding of research in the field of pharmaceutical and allied sciences.

Keywords: 

Pharmaceutical Sciences:  Pharmaceutics, Formulation Science (Solids, Topical, Parenteral NDDS), Polymer Sciences, Pharmacology & Toxicology, Nanotechnology, Medicinal Chemistry, Biopharmaceutics, Pharmacoeconomics, Pharmacognosy, Pharmacovigilance, Pharmacogenomics, Biotechnology, Pharmacoinformatics, Pharmaceutical Technology, Drug Regulatory Affairs, Pharmaceutical Technology & Analytical Chemistry etc.

Allied Sciences : Biology, Medical Sciences, Psychology, Health Outcomes Research, Evidence Based Medicine, Microbiology, Neurosciences, Pathology, Biomaterial Sciences, Natural Chemistry, Green Chemistry, Physiology, Biochemistry, Agronomy, Animal & Veterinary Sciences, Environmental Sciences, Food & Food Industry etc.

Announcement and Advertisement 

Announcements regarding scientific activities such as conferences, symposium, are published for free. Advertisements can be either published or placed on website as banners.

Publishing Schedule:  4 issues per year (January, April, July, October).

Important Links

• Conflicts of Interest
• Copyright and Access
• Editorial Policies
• Peer Review Policy
• Privacy Statement
• Publishing Ethics
• Copyright Form
• Author's Instruction
• Join Editorial Board

It’s our pleasure to inform you that, IJPPR Issue has been Published. Articles are Invited for Publication. Please send your articles to [email protected]

International Journal of Pharmacy and Pharmaceutical Research ( ijppr.humanjournals.com ) is an open access, peer reviewed international monthly journal dedicated to the latest advancement in Pharmacy and Pharmaceutical Research. The Journal and Editorial Board endeavor to attract and publish articles from a variety of disciplines and educational settings to promote excellence in pharmaceutical research.

The Journal is excited to revive the pharmacy professionals by providing services whose sole purpose is to unify and empower the pharmacy community.

Healthcare researchers are invited to submit special themed issues on scientific subjects of current interest. Submission of expert reviews and research articles in all areas of pharmaceutical sciences are welcomed.

A rapid peer-reviewing system will be maintained by the editorial staff. The articles will be solicited from the leading researchers in all fields of pharmacy and related disciplines.

SALIENT FEATURES

IJPPR covers the following areas

• February 2024
• January 2024
• December 2023
• November 2023
• October 2023
• September 2023
• August 2023
• February 2023
• January 2023
• December 2022
• November 2022
• October 2022
• September 2022
• August 2022
• February 2022
• January 2022
• December 2021
• November 2021
• October 2021
• September 2021
• August 2021
• February 2021
• January 2021
• December 2020
• November 2020
• October 2020
• September 2020
• August 2020
• February 2020
• January 2020
• December 2019
• November 2019
• October 2019
• September 2019
• August 2019
• February 2019
• January 2019
• December 2018
• November 2018
• October 2018
• September 2018
• August 2018
• February 2018
• January 2018
• December 2017
• November 2017
• October 2017
• September 2017
• August 2017
• February 2017
• January 2017
• December 2016
• November 2016
• October 2016
• September 2016
• August 2016
• February 2016
• January 2016
• December 2015
• November 2015
• October 2015
• September 2015
• August 2015
• February 2015
• January 2015
• December 2014
• November 2014
• September 2014
• August 2014

International Journal of Pharmacy and Pharmaceutical Research (IJPPR) will give the best paper award every year in the form of money along with a certificate to support the research activity of scholars.

Welcome the experts from the field of Pharmacy for the position of reviewer.

Qualification and Experience • Graduation in relevant field • Three original research papers

Please send your Resume/Bio-data with passport size photograph to:  [email protected]

Remember Me

• Lost your password?

1. Peer Review and Publication Policy

2. Publication Ethics and Malpractice Statement

• Peer Review and Publication Policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Reviewers in the relevant research area assess submitted manuscripts for originality, validity, and significance to help editors to determine whether the manuscript should be published in the journal.

Initial manuscript evaluation

The Editor first evaluates all manuscripts. It is rare, but it is possible for an exceptional manuscript to be accepted at this stage. Manuscripts rejected at this stage are insufficiently original, have serious scientific flaws, have poor grammar or English language, or are outside the aims and scope of the journal. Those that meet the editorial policies and a minimum quality level are normally passed on to at least 2 experts for review.

Type of Peer Review 

The journal employs the double-blind peer review process, where both reviewers and authors remain anonymous throughout the review process.

How the Reviewers is selected

Whenever possible, Reviewers are matched to the paper according to their expertise and our database is constantly being updated.

Reviewer’s reports

Reviewers are asked to evaluate whether the manuscript: – Is original – Is methodologically sound – Follows appropriate ethical guidelines – Has results which are clearly presented and support the conclusions – Correctly references previous relevant work.

Language correction is not part of the peer review process, but Reviewers may, if so wish, suggest corrections to the manuscript.

How long does the review process take?

The time required for the review process is dependent on the response of the Reviewers. Should the Reviewer’s reports contradict one another or a report is unnecessarily delayed, a further expert opinion will be sought. In rare cases for which it is extremely difficult to find a second Reviewers to review the manuscript, or when the one Reviewer’s report has thoroughly convinced the Editor, decisions at this stage to accept, reject or ask the author for a revision are made on the basis of only one Reviewer’s report. The Editor’s decision will be sent to the author with recommendations made by the Reviewers, which usually includes verbatim comments by the Reviewers. Revised manuscripts might be returned to the initial Reviewers who may then request another revision of a manuscript.

Final report 

A final decision to accept or reject the manuscript will be sent to the author along with any recommendations made by the Reviewers and may include verbatim comments by the Reviewers.

Editor’s Decision is final

Reviewers advise the editor, who is responsible for the final decision to accept or reject the article.

• PUBLICATION ETHICS AND MALPRACTICE STATEMENT

It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editor, the peer reviewer and the publisher. Our ethic statements are based on  COPE’s Best Practice Guidelines  for Journal Editors.

The journal is dedicated to following best practices on ethical matters, errors, and retractions. Any kind of unethical behavior is not acceptable, and the Editorial board do not tolerate plagiarism in any form.

Authors submitting articles to journal affirm that manuscript contents are original.

Duties of Editors

• Publication decisions : The editors at the Journal are responsible for deciding which of the articles submitted to the journal should be published. The editor may be guided by the policies of the journal’s editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers in making this decision.
• Fair play : An editor at any time evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.
• Confidentiality : The editor and any editorial staff must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.
• Disclosure and conflicts of interest : Unpublished materials disclosed in a submitted manuscript must not be used in an editor’s own research without the express written consent of the author.

Duties of Reviewers

• Contribution to Editorial Decisions : Peer reviewer assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper.
• Promptness : Any selected reviewer who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process.
• Confidentiality : Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorized by the editor.
• Standards of Objectivity : Reviews should be conducted objectively. Personal criticism of the author is inappropriate. The reviewer should express their views clearly with supporting arguments.
• Acknowledgment of Sources : Reviewers should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor’s attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
• Disclosure and Conflict of Interest : Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

Duties of Authors

• Reporting standards : Author’s reports of original research should be presented an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.
• Data Access and Retention : Authors are asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.
• Originality and Plagiarism : The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others that this has been appropriately cited or quoted.
• Multiple, Redundant or Concurrent Publication : An author should not in general publish manuscripts describing essentially the same research in more than one journal or primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable.
• Acknowledgment of Sources : Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work.
• Authorship of the Paper : Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included in the paper and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.
• Hazards and Human or Animal Subjects : If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.
• Disclosure and Conflicts of Interest : All authors should disclose in their manuscript any financial or other substantive conflicts of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.
• Fundamental errors in published works : When an author discovers a significant error or inaccuracy in his/her own published work, it is the author’s obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper.

Retraction Policy

When plagiarism has been found to have occurred, the Editorial Board will take the actions as determined by the type of plagiarism. Unless determined otherwise during the investigation, all authors are deemed to be individually and collectively responsible for the content of a plagiarizing paper. Editorial Board places the investigation of each claim of plagiarism at the highest priority for resolution and action.

Action(s) in case of plagiarism in a published article and proven misconduct:

• A letter is sent to authors involved in. They are informed about the perpetrated act.
• Intimation to Author’s University/ Department about the incident of misconduct.
• Blacklisting of all Authors involved in the article, banning them to publish any content with Journal.
• PDF of the article will no longer be available online.
• The initial PDF document will be replaced by a retraction note.
• We pursue the retraction of this article from other online indexing services.

Copyright Policy

All papers in the journal are licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, even commercially as long as the original work is properly cited.

Authors retain copyright of their work. Once the material has been accepted for publication, authors are asked to sign a copyright form verifying that they have the right to publish the material and that they grant permission to the journal to publish their work online. In addition:

• Authors retain the right to publish extended versions of their material elsewhere, provided the original publication is acknowledged.
• Authors retain the right to publish their work in online repositories, internal technical reports, etc.
• Journal does not pay honoraria to authors.
• Journal has the right to edit the material to meet the publication standards.

HUMAN JOURNALS

Journal of Pharmaceutical Research International

Abstracting, indexing, other related databases, catalogue, reference citation etc..

A dedicated journal indexing team is working to include all of our journals in reputed indexing services or journal evaluation services or catalogue or reference citations, etc.  Authors should cross-check the authenticity of claims of indexing before submitting to any publisher (including our journal). We strongly encourage authors to take 'informed decision' before submission of any manuscript. In order to help the authors to take 'informed decision', we are providing web-links/proofs beside most of our claims of indexing or journal evaluation services. In addition, authors should visit the official site of the indexing organization or journal evaluation services before submitting any manuscript. We hope scholarly communities will appreciate our efforts to maintain integrity and transparency.   

1. Web of Science (ISI Thomson Reuters) (Emerging Sources Citation Index) (DISCONTINUED)

Journal Citation Report TM (JCR) 2021

 Proof:   https://journaljpri.com/img/JPRI-JCR.jpeg

2.   US National Library of Medicine (NLM) Catalog (NLM ID: 101716968)  (see  ftp.ncbi.nih.gov/pubmed/J_Medline.txt ) (Proof: http://bit.ly/PUBMED-jpri ) 

3. Index Copernicus  ICV: 100.00 (Proof: http://bit.ly/Index-Copernicus-JPRI )

4. Publons  

5. CNKI (China)  

6. Polish Ministry of Science and Higher Education  ( Original link )

7. ProQuest 

8. EBSCO (Proof: http://bit.ly/ebsco-sdi-proof )

9. Chemical Abstracts Service (American Chemical Society)  (Proof: https://bit.ly/CASSI-JPRI )

Journal of Pharmaceutical Research International (ISSN: 2456-9119) (Past name: British Journal of Pharmaceutical Research; ISSN: 2231-2919)

10. Semanticscholar

12. Scite Index (2021):        Link:  https://scite.ai/journals/journal-of-pharmaceutical-research-international-5GKNp

13.   NAAS Score: 5.51 (2020) (Proof:  https://tinyurl.com/NAAS-2020 )

14. SDG Publishers Compact

15. Google Scholar  https://scholar.google.com (h5-index: 10 and h5-median: 12) 

16. PubMED: We have already officially applied for PubMED indexing of our relevant journals by following the strict technical evaluation rules of PubMED.  Some of our papers are appearing in PUBMED (Following: http://publicaccess.nih.gov/submit_process.htm#c  (Author submitted papers) (Method C)).

17. SHERPA/RoMEO  (UK) ( http://sherpa.ac.uk/romeo/search.php?issn=2231-2919 )

18. CrossRef ( https://doi.org/10.9734/JPRI )

19. The Keepers Registry (Proof: https://portal.issn.org/resource/ISSN/2456-9119 )

20. WorldCAT ( https://www.worldcat.org/ )

21. ScienceOpen (Proof:  https://bit.ly/ScienceOpen-JPRI )

22. JournalTOCs (Proof:  https://bit.ly/JournalTOCs-JPRI )

23. Elektronische Zeitschriftenbibliothekï EZB

24. Zeitschriften Datenbank (ZDB)

25. Quality Open Access Market (QOAM)

27. Citefactor (https://www.citefactor.org/)

28. ResearchGate

29. Bridge of Knowledge

30. ACADEMIA (https://www.academia.edu)

31. iSEEK (http://education.iseek.com/iseek/home.page)

32. RefSEEK (https://www.refseek.com/)

33. WorldWideScience (https://worldwidescience.org/)

34. Bielefeld Academic Search (https://www.base-search.net/)

37. Analytical sciences digital library

38. CiteSeerX (https://citeseerx.ist.psu.edu)

39. INSPIRE-HEP (http://inspirehep.net/?ln=en)

40. Mendeley

41. OAIster

42. OpenSIGLE

43. Paperity

46. CORE (https://core.ac.uk/)

47. Baidu Scholar

48. Sparrho (https://www.sparrho.com/)

49. Journalseek (http://journalseek.net/)

© Copyright 2010-Till Date, Journal of Pharmaceutical Research International. All rights reserved.

International Journal of Current Pharmaceutical Research

• Current Issue
• Vol 1, Issue 1
• Vol 2, Issue 1
• Vol 2, Issue 2
• Vol 2, Issue 3
• Vol 2, Issue 4
• Vol 3, Issue 1
• Vol 3, Issue 2
• Vol 3, Issue 3
• Vol 3, Issue 4
• Vol 4, Issue 1
• Vol 4, Issue 2
• Vol 4, Issue 3
• Vol 4, Issue 4
• Vol 5 Issue 1
• Vol 5 Issue 2
• Vol 5 Issue 3
• Vol 6 Issue 1
• Vol 6 Issue 2
• Vol 6 Issue 3
• Vol 6 Issue 4
• Vol 7 Issue 1
• Vol 7 Issue 2
• Instructions
• Manuscript Submission
• Editorial Board

Welcome to IJCPR

The Journal publishes original research work that contributes significantly to further the scientific knowledge in pharmacy and pharmaceutical sciences (Pharmaceutical Technology, Pharmacognosy, Natural Product Research, Pharmaceutics, Novel Drug Delivery, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacology,Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology,Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest). The Journal publishes original research work either as a Full Research Paper or as a Short Communication. Review Articles on a current topic in the said fields are also considered for publication by the Journal.

Abstracting and Indexing : Google scholar, IndexCopernicus, DOAJ, PSOAR, Open-J-Gate, Indian Citation Index (ICI), OAI, LOCKKS, OCLC (World Digital Collection Gateway), UIUC.

Scientific Journal Impact Factor-  4 . 510  (SJIF 2013 )

ICV (2011) – 4.70

Journals of Innovare Academic Sciences have made their presence in short span of time amongst International community with great impact ICV- 4.50, 4.28, 4.20, 3.38 .

• Visit New Website (Click Here)
• IJCPR Subscription
• Latest & Future Issues
• AJPCR Journals Asian Journal of Pharmaceutical and Clinical Research
• IJAP Journals International Journal of Applied Pharmaceutics
• IJCR Journals International Journal of Chemistry Research
• IJPPS Journals International Journals of Pharmacy and Pharmaceutical Science

Contact Us || Terms of Use || Privacy Statement Copyright © 2009 IJCPR All Rights Reserved.

Designed & Developed by Anchal Kesharwani . @ CyberDairy Solutions

International Journal of Medical and Pharmaceutical Research

Welcome to IJMPR (Online ISSN-2958-3683 ; Print ISSN-2958-3675)

A PHP Error was encountered

Severity: Notice

Message: Undefined variable: index

Filename: views/index.php

Line Number: 111

File: /home/ijmprinm/public_html/application/views/index.php Line: 111 Function: _error_handler

File: /home/ijmprinm/public_html/application/controllers/Main.php Line: 35 Function: view

File: /home/ijmprinm/public_html/index.php Line: 316 Function: require_once

Message: Trying to get property 'index_picture' of non-object

Browse Menu

Best Indexing

Track your article

 Userfull Links

 Why us?

Recently Published Papers

A Study On Oligohydramnios and Its Perinatal Outcome

Background : Oligohydramnios is one of the major causes of perinatal morbidity and mortality. The sonographic diagnosis of oligohydramnios is usually based on an AFI≤5     cm or on a single deepest pocket of amniotic fluid≤2 cm.Our study was aimed to study the perinatal outcome in oligohydramnios. Aim and objective were to study maternal outcome in the form of mode of delivery, and to assess neonatal complications in terms of APGAR score at birth, NICU admission rates, meconium stained liquor in oligohydramnios. Methods: This prospective study was done among 90 patients with gestational age from 28 - 42wks with Oligohydramnios AFI7 (83%) in most cases. Most common cause of NICU admission is meconium aspiration syndrome (8.88%). Conclusion: AFI is an important and convenient screening test for prediction of perinatal outcome. In presence of oligohydramnios, the risk of fetal distress, operative delivery, low Apgar score, low birth weight, perinatal morbidity and mortality are more. Hence   early detection of oligohydramnios, associated antenatal risk factors and timely management can improve the maternal and fetal outcome.

  A Study On Oligohydramnios and Its Perinatal Outcome

 Dr. Medapati Divya Reddy, Dr. Machavarapu Krishna Deepthi , Dr. S. Harshavardhan , Dr. J.V.Narasimha Rao

Modal Header

Some text in the modal.

Comparison of Negative Pressure Wound Therapy and Traditional Dressings in Diabetic Foot Ulcer Patients

Background: Diabetic foot ulcers (DFUs) pose a significant challenge in diabetes care, with varying treatments available. This study compared the efficacy of Negative Pressure Wound Therapy (NPWT) with traditional dressings in DFUs management. Methods: A prospective, randomized comparative study was conducted involving 120 patients with DFUs, divided equally between NPWT and traditional dressings groups. The primary outcomes measured were healing time, wound healing rates at 4, 8, and 12 weeks, infection rates, and incidence of complications. Results: NPWT significantly reduced the mean healing time to 6.8 weeks compared to 9.5 weeks for traditional dressings (p < 0.001). Healing rates at 4, 8, and 12 weeks were significantly higher in the NPWT group (30%, 60%, and 78%, respectively) compared to the traditional dressings group (18%, 40%, and 58%, respectively) with p-values of 0.045, 0.03, and 0.023. The NPWT group also showed a lower infection rate (10% vs. 25%, p = 0.015) and fewer complications, including rates of gangrene (3.3% vs. 10%, p = 0.038) and amputation (1.7% vs. 8.3%, p = 0.042). Conclusion: NPWT offers significant advantages over traditional dressings in the management of DFUs, including faster healing, higher healing rates, reduced infection rates, and lower incidence of severe complications. These findings support the preference for NPWT in DFU treatment protocols, considering individual patient conditions.

  Comparison of Negative Pressure Wound Therapy and Traditional Dressings in Diabetic Foot Ulcer Patients

 Dr Sankalpa NS, Dr Vedavathi K Nandhini, Dr Ramanahalli Saikiran

Remarks on Metabolic Health Conference 2024: In light of personal experience and scientific literature

This article aims to provide a remark on the second Metabolic Health Conference (MHC2), which was recently held from April 26 to 28, 2024. The authors are researchers who participated in MHC-2 as speakers and wanted to provide a remark which should reach diverse professionals and members of the public. The authors formulate this remark by using their personal experience at the conference and critically reflecting on the relevant scientific literature. This article finds the following.

While India  needs novel approaches to  address  its increasing  metabolic health issues, and  while  adopting such  approaches is  challenging, the Metabolic  Health Conferences (MHCs) serve as a promising hope. Moreover, the first Metabolic Health Conference (MHC-1) and MHC-2 fill the gap of roughly 115 years, as within this span,  it is hard to find a conference exclusively dedicated to discussing the low-carbohydrate approach in light of diabetes and metabolic syndrome in India.

Additionally, because of MHC-1 and MHC-2, for the first time in the history of the Indian low-carbohydrate movement, numerous stakeholders—researchers, doctors, health professionals, and organisations—across the globe united to discuss the lowcarbohydrate approach in light of the Indian population's diverse metabolic health issues. These conferences are an essential resource for contemporary and future researchers and practitioners. Therefore, MHC-1 and MHC-2 are pivotal in reshaping Indian public health

  Remarks on Metabolic Health Conference 2024: In light of personal experience and scientific literature

 Abhinav Vitthalrao Pathare,Anup Bhaskarrao Chaudhary

Excessive dynamic airway collapse presenting as intractable cough and wheezing : A case report

Excessive dynamic airway collapse (EDAC) is a condition characterized by significant airway narrowing, often mistaken for asthma or COPD. This case study highlights a 35-year-old woman with chronic cough and wheezing, resistant to standard treatments. Through bronchoscopy, EDAC (>90%) was diagnosed, exacerbated by a history of pulmonary tuberculosis. Treatment involved serial bronchial dilatation and NIPPV, resulting in symptom relief. EDAC, frequently underdiagnosed, warrants consideration in patients with refractory respiratory symptoms, especially those with past tuberculosis. Dynamic bronchoscopy remains the gold standard for diagnosis, guiding tailored management strategies ranging from conservative to surgical interventions.

  Excessive dynamic airway collapse presenting as intractable cough and wheezing : A case report

 Singh B.P; Pandey Amit Kumar; Singh Apoorva; Kumar Krishan; Palekar Santosh; Patel mehul Darshak; Tiwari Anubha; Gehlot Yogesh

A Comparative Prospective Study of Open Method Repair Versus Laparoscopic Intraperitoneal On Lay Mesh (IPOM) Plus Repair For Small-Small-Ventral Hernia

Background: Any hole in the abdominal wall in the midline (vertical center) is considered a small-ventral hernia. There are two types: natural (primary) and learned (secondary). Epigastric hernia, which affects the stomach area, Umbilical hernia, which affects the belly button, and Incisional hernia, which affects the abdominal wall, are the three most common types of small-ventral hernia . Objective: To conduct a comparative analysis between laparoscopic e-TEP and IPOM techniques for small-ventral hernia repair. Methods: The present investigation was conducted as a prospective observational comparative study. The study's sample size consisted of 30 participants, with 15 instances sourced from e-TEP and the remaining 15 cases sourced from IPOM. The trial duration spanned from December 2020 to December 2022. The study employed a stratified sample strategy, which involved establishing an age eligibility condition for the respondents. The participants who underwent hernia repair treatment were included in this study through a random selection process . Results: The e-TEP group had a shorter operative time of 105.32 ± 21.44 days compared to the IPOM group's 73.83 ± 6.35 days. There were no intraoperative problems and no drains were inserted. Patients in the e-TEP group experienced a significant reduction in pain levels at both 12-hour and 24-hour time points, while the IPOM Plus group had a higher cumulative parenteral analgesia demand. The mean hospital stay was 1.11 days, significantly less than the IPOM Plus group's 1.7 days. No surgical site infections, postoperative ileus, or mesh infections were observed. Three patients had asymptomatic postoperative seroma, and conservative management was employed. No readmissions occurred in the IPOM Plus group, but two patients in the e-TEP group were admitted due to recurrence within a 6-month follow-up period. Both patients were treated using the IPOM Plus technique, and adhesiolysis procedures were successfully performed without intestinal injury. Conclusion: The e-TEP treatment is a dynamic technique that can be likened to IPOM Plus in relation to factors like as postoperative discomfort, painkiller usage, mesh expenses, and duration of hospitalization.

  A Comparative Prospective Study of Open Method Repair Versus Laparoscopic Intraperitoneal On Lay Mesh (IPOM) Plus Repair For Small-Small-Ventral Hernia

 Md. Atiqul Haque Sarder; Muhammad Alom; Sabran Uddin

Clinical Profile and Outcome of Leptospirosis in Tertiary Care Center Karwar, UK District

Background : Leptospirosis remains a vital health concern in tropical regions, with varying clinical presentations, complications, and outcomes. This study offers a comprehensive insight into leptospirosis diagnosed at the Karwar Institute of Medical Sciences.

Methods : A retrospective analysis of 50 patients diagnosed between January 2020 and December 2021 was conducted. Clinical manifestations, laboratory parameters, complications, and outcomes were documented and analyzed.

Results : Predominance was observed among 21-40 year-olds (50%) and males (70%). Major exposure routes included water-related activities (40%), animal contact (30%), and agricultural work (20%). Clinical presentation primarily comprised fever (90%), muscle pain (80%), and jaundice (50%). Laboratory diagnostics revealed an average ELISA titer of 1:800 and a slightly elevated mean WBC count of 11.2 x10^9/L. Renal failure emerged as a significant complication (20%). Patient outcomes depicted 64% recovering without complications, while 2% mortality was recorded. Multivariate analysis identified age above 40, jaundice at presentation, and thrombocytopenia as potent risk factors for severe complications.

Conclusion : Leptospirosis in the Karwar region presents unique demographic and clinical patterns. While the findings echo global trends in many respects, distinct regional characteristics necessitate tailored interventions. Comprehensive awareness, early diagnosis, and targeted treatment strategies are imperative to manage and mitigate the disease's impact effectively.

  Clinical Profile and Outcome of Leptospirosis in Tertiary Care Center Karwar, UK District

 Dr. Nandakumar CS; Dr. Raju Talawar

Comparative Outcomes of Laparoscopic versus Open Hernia Repair A Prospective, Randomized Single centre Study

Background : Inguinal hernia repair is one of the most commonly performed surgical procedures worldwide. Laparoscopic hernia repair has gained popularity due to its potential benefits, but its superiority over open repair remains controversial.

Objective : To compare the outcomes of laparoscopic versus open hernia repair in patients with primary, unilateral, reducible inguinal hernias.

Methods : This prospective, randomized single-center study included 100 patients who were randomly allocated to either laparoscopic (n=50) or open (n=50) hernia repair. Postoperative pain, analgesic requirement, hospital stay, return to normal activities, complications, and recurrence rates were assessed.

Results : Laparoscopic repair was associated with significantly lower postoperative pain scores at 24 hours (3.8 ± 1.6 vs. 5.2 ± 1.8, p<0.001), 48 hours (2.6 ± 1.4 vs. 4.1 ± 1.7, p<0.001), and 7 days (1.4 ± 1.1 vs. 2.5 ± 1.3, p<0.001). The laparoscopic group had a shorter hospital stay (1.6 ± 0.8 vs. 2.4 ± 1.1 days, p<0.001) and faster return to normal activities (10.2 ± 3.6 vs. 15.8 ± 4.2 days, p<0.001). The incidence of chronic pain was lower in the laparoscopic group at 3 months (4% vs. 16%, p=0.04) and 6 months (2% vs. 12%, p=0.05). Recurrence rates were similar between the groups at 2 years (4% vs. 6%, p=0.65).

Conclusion : Laparoscopic hernia repair is associated with reduced postoperative pain, shorter hospital stay, faster recovery, and lower rates of chronic pain compared to open repair, with similar recurrence rates at 2 years. These findings support the use of laparoscopic repair as the preferred approach for primary, unilateral, reducible inguinal hernias.

  Comparative Outcomes of Laparoscopic versus Open Hernia Repair A Prospective, Randomized Single centre Study

 Dr Chetan Gotur; Dr Prashant Shetty

Malignant Peripheral Nerve Sheath Tumour Of Hypoglossal Nerve: A Case Report

A 55-year-old woman presented with symptomatic malignant peripheral nerve sheath tumor (MPNST) of the right hypoglossal nerve, characterized by six months of pain radiating to the right ear, headaches, and swelling over the submandibular region. Initial diagnosis was confirmed through a biopsy, and the treatment regimen included surgical resection followed by radiation therapy.

About half of MPNSTs, an uncommon kind of soft tissue sarcoma, are linked to a mutation in Neurofibromatosis type 1 (NF1), with the remaining cases being random. Because these tumors are rare and aggressive, they frequently pose difficulties for diagnosis and treatment. This case presents a unique clinical setting due to the unusual involvement of the hypoglossal nerve.

A multidisciplinary strategy is usually used in the therapy of MPNST, with surgery serving as the main treatment to establish local control. In order to lower the chance of recurrence, radiation therapy is frequently used after surgery. Depending on the patient's state and the behavior of the tumor, chemotherapy might be considered in some circumstances.

This case highlights the necessity of considering MPNST in differential diagnoses for patients with similar symptoms, particularly in those with NF1. Early detection and comprehensive treatment are essential for improving patient outcomes in such complex and rare malignancies.

  Malignant Peripheral Nerve Sheath Tumour Of Hypoglossal Nerve: A Case Report

 Dr. Sharath Sreeni; Dr. Vaishnavi Perumareddy; Dr. Satyabrata Kanungo; Ms. Shrutisikha Goswami; Dr. Susmita Sarma

A Study of Autopsy Cases of Sudden Death

Background: Sudden death is defined by WHO as “Deaths within 24 hours from the onset of the symptoms.” Sudden death is a traumatic event for the family, it has huge social and psychological consequences and is also a major contributor to years of life lost among the young. The causes of sudden death differ greatly among various age groups and it includes cardiovascular causes, pulmonary causes like thromboembolism, anaphylaxis, severe pneumonia, other causes like intracranial haemorrhage, gastrointestinal causes etc.

Aim : To study and classify the underlying causes of sudden death.

Materials and Method: A review of autopsy cases of sudden death was performed between August 2023 to December 2023 at the department of pathology, SMIMER medical college, Surat. Out of 210 total autopsy cases received during that period, 50 cases(23.8%) were studied for sudden deaths. Specimens were fixed in 10% formalin for fixation, grossing was done and representative sections were taken. Tissue processing was done according to standard protocol, routine Haematoxylin and Eosin staining was done and special stain was done whenever required.

Results: Out of 210 total autopsy cases received from August 2023 to December 2023, 50 cases(23.8%) were studied for  sudden deaths. The age group with most cases of sudden death was 45 – 59 years. Males(88%) were affected more than female (12%)with male to female ratio of 7.3:1. The most common cause of sudden death comprised of cardiac causes(60%),in which CAD consists of 54% followed by myocarditis-04% and Cardiomyopathy- 02%, while deaths by respiratory causes(6%) comprises of deaths due to pneumonia(4%) and Tuberculosis of lung (2%),other systemic causes(4%) consists of cirrhosis of liver (hepatobiliary system-2%) and leukemia(Hematopoietic system-2%).

Conclusion: Meticulous autopsy and proper histopathological examination play an important role to find out the cause of sudden death.The most common cause of sudden death is attributed to cardiac causes. This study makes us aware about the serious health issues faced by our society.

  A Study of Autopsy Cases of Sudden Death

 Dr. Pranjal Rajani; Dr. Niketa Roy; Dr. Ashwini Shukla

Functional Outcome of Supraspinatus Tendon Tear Treated with Open Supraspinatus Tendon Repair with Suture Anchors

Introduction : The supraspinatus plays an important role in GH joint stability and is responsible for initiating abduction and rotation of the joint as well as compression at lower elevation angles. Tears of the rotator cuff ( Supraspinatus) of the shoulder are potentially painful and disabling conditions. The person with a Supraspinatus tear can have a sudden (acute/traumatic) or gradual (chronic) onset of shoulder pain with or without weakness. Treatments for Supraspinatus tears vary widely depending upon the severity of symptoms and signs.

Material and Methods :. A prospective study design was carried out from the month of April 2022 to December 2023, 20 patients were included in this study and  have been followed up till December 2023 and the functional outcome was measured based on constant- Murley shoulder outcome score.

Results :.  90% of the patients had excellent to good outcomes. Preoperative constant-murley score on an average was 56-70 points with a mean of 68 and postoperavtive constant- murley shoulder outcome score of 86-100 points with a mean of 98 showing excellent results. Suture anchor repairs restored supraspinatus mechanical properties after 8 postoperative weeks. All patients have resorted back to routine work after 4 months period.

Conclusion : Open Supraspinatus repair with Suture anchors procedure offers a good surgical method of management of Supraspinatus tendon tear and to restore the functional outcome. Anchor repair provided better initial tensile strength and early mobilization of patient.

  Functional Outcome of Supraspinatus Tendon Tear Treated with Open Supraspinatus Tendon Repair with Suture Anchors

 Kandi Arun Kumar; V Nageswara Rao; N V Ramesh Kumar; Y Maniraj Chowdary

Notifications

IJMPR is an international open access source for a high quality and peer reviewed journal in the fields of Medical and Pharmaceutical Sciences. IJMPR publishes research papers across all academic disciplines in the fields of Medical, Pharmaceutical Sciences.

Information

• Author Services

Initiatives

You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .

Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.

Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.

Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.

Original Submission Date Received: .

• Active Journals
• Find a Journal
• Proceedings Series
• For Authors
• For Reviewers
• For Editors
• For Librarians
• For Publishers
• For Societies
• For Conference Organizers
• Open Access Policy
• Institutional Open Access Program
• Special Issues Guidelines
• Editorial Process
• Research and Publication Ethics
• Article Processing Charges
• Testimonials
• Preprints.org
• SciProfiles
• Encyclopedia

Article Menu

• Subscribe SciFeed
• Recommended Articles
• Google Scholar
• on Google Scholar
• Table of Contents

Find support for a specific problem in the support section of our website.

Please let us know what you think of our products and services.

Visit our dedicated information section to learn more about MDPI.

JSmol Viewer

Attention deficit hyperactivity disorder: a risk factor for premature discontinuation of inpatient opioid withdrawal treatment.

1. Introduction

2. materials and methods, 2.1. procedures and study design, 2.2. psychometric inventories, 3.1. clinical and sociodemographic characteristics of the participants, 3.2. adhd-sr, wurs-k, and diva 2.0, 4. discussion, 5. conclusions, author contributions, institutional review board statement, informed consent statement, data availability statement, acknowledgments, conflicts of interest.

• Lee, Y.K.; Gold, M.S.; Blum, K.; Thanos, P.K.; Hanna, C.; Fuehrlein, B.S. Opioid use disorder: Current trends and potential treatments. Front. Public Health 2023 , 11 , 1274719. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Suen, L.W.; Makam, A.N.; Snyder, H.R.; Repplinger, D.; Kushel, M.B.; Martin, M.; Nguyen, O.K. National Prevalence of Alcohol and Other Substance Use Disorders Among Emergency Department Visits and Hospitalizations: NHAMCS 2014–2018. J. Gen. Intern. Med. 2022 , 37 , 2420–2428. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Khanjani, M.S.; Younesi, S.J.; Abdi, K.; Mardani-Hamooleh, M.; Sohrabnejad, S. Prevalence of and Factors Influencing Suicide Ideation, Attempt, and Completion in Heroin Users: A Systematic Review and Meta-Analysis. Addict. Health 2023 , 15 , 119–127. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Schindler, S.-D.; Ortner, R.; Peternell, A.; Eder, H.; Opgenoorth, E.; Fischer, G. Maintenance therapy with synthetic opioids and driving aptitude. Eur. Addict. Res. 2004 , 10 , 80–87. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Ali, S.; Tahir, B.; Jabeen, S.; Malik, M. Methadone Treatment of Opiate Addiction: A Systematic Review of Comparative Studies. Innov. Clin. Neurosci. 2017 , 14 , 8–19. [ Google Scholar ] [ PubMed ]
• Schoofs, N.; Riemer, T.; Bald, L.K.; Heinz, A.; Gallinat, J.; Bermpohl, F.; Gutwinski, S. Methadone and levomethadone—Dosage and side effects. Psychiatr. Prax. 2014 , 41 , 82–87. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Shulman, M.; Wai, J.M.; Nunes, E.V. Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS Drugs 2019 , 33 , 567–580. [ Google Scholar ] [ CrossRef ]
• Ferri, M.; Davoli, M.; Perucci, C.A. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst. Rev. 2011 , 2011 , CD003410. [ Google Scholar ] [ CrossRef ]
• Brooks, O.; Ng, J.C.B.; Ickowicz, S. Outpatient Rapid Titration of Slow Release Oral Morphine for the Treatment of Opioid Use Disorder in a Canadian Setting: A Case Series. J. Addict. Med. 2023 , 17 , e240–e245. [ Google Scholar ] [ CrossRef ]
• Wang, J.; Deane, F.P.; Kelly, P.J.; Robinson, L. A narrative review of outcome measures used in drug and alcohol inpatient withdrawal treatment research. Drug Alcohol Rev. 2023 , 42 , 415–426. [ Google Scholar ] [ CrossRef ]
• Wang, J.; Deane, F.P.; Kelly, P.J.; Robinson, L.D. Goals and Reasons for Entering Inpatient Withdrawal Treatment, and Perceptions of Help Received. J. Dual Diagn. 2023 , 19 , 166–176. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Taylor, J.L.; Samet, J.H. Opioid Use Disorder. Ann. Intern. Med. 2022 , 175 , ITC1–ITC16. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Santo, T., Jr.; Campbell, G.; Gisev, N.; Martino-Burke, D.; Wilson, J.; Colledge-Frisby, S.; Clark, B.; Tran, L.T.; Degenhardt, L. Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2022 , 238 , S124. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Mariani, J.J.; Levin, F.R. Treatment strategies for co-occurring ADHD and substance use disorders. Am. J. Addict. 2007 , 16 (Suppl. S1), 45–56. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Beckmann, D.; Lowman, K.L.; Nargiso, J.; McKowen, J.; Watt, L.; Yule, A.M. Substance-induced Psychosis in Youth. Child Adolesc. Psychiatr. Clin. N. Am. 2020 , 29 , 131–143. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• West, M.L.; Sharif, S. Cannabis and Psychosis. Child Adolesc. Psychiatr. Clin. N. Am. 2023 , 32 , 69–83. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Bohus, M.; Stoffers-Winterling, J.; Sharp, C.; Krause-Utz, A.; Schmahl, C.; Lieb, K. Borderline personality disorder. Lancet 2021 , 398 , 1528–1540. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Donald, F.; Arunogiri, S.; I Lubman, D. Substance use and borderline personality disorder: Fostering hope in the face of complexity. Australas. Psychiatry 2019 , 27 , 569–572. [ Google Scholar ] [ CrossRef ]
• Moura, H.F.; Faller, S.; Benzano, D.; Szobot, C.; Von Diemen, L.; Msc, A.R.S.; Msc, M.L.S.-F.; Cruz, M.S.; Brasiliano, S.; Pechansky, F.; et al. The effects of ADHD in adult substance abusers. J. Addict. Dis. 2013 , 32 , 252–262. [ Google Scholar ] [ CrossRef ]
• Simon, V.; Czobor, P.; Bálint, S.; Mészáros, Á.; Bitter, I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. Br. J. Psychiatry 2009 , 194 , 204–211. [ Google Scholar ] [ CrossRef ]
• Polanczyk, G.V.; Willcutt, E.G.; Salum, G.A.; Kieling, C.; Rohde, L.A. ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. Int. J. Epidemiol. 2014 , 43 , 434–442. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Austerman, J. ADHD and behavioral disorders: Assessment, management, and an update from DSM-5. Clevel. Clin. J. Med. 2015 , 82 (Suppl. 1), S2–S7. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• A Barkley, R.; Fischer, M.; Smallish, L.; Fletcher, K. Young adult outcome of hyperactive children: Adaptive functioning in major life activities. J. Am. Acad. Child Adolesc. Psychiatry 2006 , 45 , 192–202. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Vahia, V.N. Diagnostic and Statistical Manual of Mental Disorders , 4th ed.; American Psychiatric Association: Washington, DC, USA, 1994. [ Google Scholar ]
• Salvi, V.; Migliarese, G.; Venturi, V.; Rossi, F.; Torriero, S.; Vigano, V.; Cerveri, G.; Mencacci, C. ADHD in adults: Clinical subtypes and associated characteristics. Riv. Psichiatr. 2019 , 54 , 84–89. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Cortese, S.; Adamo, N.; Del Giovane, C.; Mohr-Jensen, C.; Hayes, A.J.; Carucci, S.; Atkinson, L.Z.; Tessari, L.; Banaschewski, T.; Coghill, D.; et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry 2018 , 5 , 727–738. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Kendall, T.; Taylor, E.; Perez, A.; Taylor, C. Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: Summary of NICE guidance. BMJ 2008 , 337 , a1239. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Lee, S.S.; Humphreys, K.L.; Flory, K.; Liu, R.; Glass, K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review. Clin. Psychol. Rev. 2011 , 31 , 328–341. [ Google Scholar ] [ CrossRef ]
• Bassiony, M.M.; Salah El-Deen, G.M.; Ameen, N.; Mahdy, R.S. Prevalence, correlates, and consequences of attention-deficit/hyperactivity disorder in a clinical sample of adults with tramadol use in Egypt. Am. J. Addict. 2022 , 31 , 31–36. [ Google Scholar ] [ CrossRef ]
• Crunelle, C.L.; Brink, W.v.D.; Moggi, F.; Konstenius, M.; Franck, J.; Levin, F.R.; van de Glind, G.; Demetrovics, Z.; Coetzee, C.; Luderer, M.; et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur. Addict. Res. 2018 , 24 , 43–51. [ Google Scholar ] [ CrossRef ]
• Oortmerssen, K.v.E.-V.; van de Glind, G.; Brink, W.v.D.; Smit, F.; Crunelle, C.L.; Swets, M.; Schoevers, R.A. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: A meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012 , 122 , 11–19. [ Google Scholar ] [ CrossRef ]
• Carpentier, P.; van Gogh, M.; Knapen, L.; Buitelaar, J.; De Jong, C. Influence of attention deficit hyperactivity disorder and conduct disorder on opioid dependence severity and psychiatric comorbidity in chronic methadone-maintained patients. Eur. Addict. Res. 2010 , 17 , 10–20. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Wise, B.K.; Cuffe, S.P.; Fischer, T. Dual diagnosis and successful participation of adolescents in substance abuse treatment. J. Subst. Abus. Treat. 2001 , 21 , 161–165. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Levin, F.R.; Evans, S.M.; Vosburg, S.K.; Horton, T.; Brooks, D.; Ng, J. Impact of attention-deficit hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community. Addict. Behav. 2004 , 29 , 1875–1882. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Quinn, P.D.; Hur, K.; Chang, Z.; Krebs, E.E.; Bair, M.J.; Scott, E.L.; Rickert, M.E.; Gibbons, R.D.; Kroenke, K.; D’Onofrio, B.M. Incident and long-term opioid therapy among patients with psychiatric conditions and medications: A national study of commercial health care claims. Pain 2017 , 158 , 140–148. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Dalsgaard, S.; Mortensen, P.B.; Frydenberg, M.; Thomsen, P.H. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood—A naturalistic long-term follow-up study. Addict. Behav. 2014 , 39 , 325–328. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Zulauf, C.A.; Sprich, S.E.; Safren, S.A.; Wilens, T.E. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr. Psychiatry Rep. 2014 , 16 , 436. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Barbuti, M.; Maiello, M.; Spera, V.; Pallucchini, A.; Brancati, G.E.; Maremmani, A.G.I.; Perugi, G.; Maremmani, I. Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician. J. Clin. Med. 2023 , 12 , 3096. [ Google Scholar ] [ CrossRef ]
• Scherbaum, N.; Heppekausen, K.; Rist, F. Is premature termination of opiate detoxification due to intensive withdrawal or craving? Fortschr. Neurol. Psychiatr. 2004 , 72 , 14–20. [ Google Scholar ] [ CrossRef ]
• Urcelay, G.P.; Dalley, J.W. Linking ADHD, impulsivity, and drug abuse: A neuropsychological perspective. Curr. Top Behav. Neurosci. 2012 , 9 , 173–197. [ Google Scholar ] [ CrossRef ]
• World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders ; World Health Organization: Geneva, Switzerland, 1993. [ Google Scholar ]
• Mateos-Díaz, A.-M.; Marcos, M.; Chamorro, A.-J. Wernicke-Korsakoff syndrome and other diseases associated with thyamine deficiency. Med. Clin. 2022 , 158 , 431–436. [ Google Scholar ] [ CrossRef ]
• Retz-Junginger, P.; Retz, W.; Blocher, D.; Weijers, H.G.; Trott, G.E.; Wender, P.H.; Rössler, M. Wender Utah rating scale. The short-version for the assessment of the attention-deficit hyperactivity disorder in adults. Nervenarzt 2002 , 73 , 830–838. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Rösler, M.; Retz, W.; Retz-Junginger, P.; Thome, J.; Supprian, T.; Nissen, T.; Stieglitz, R.D.; Blocher, D.; Hengesch, G.; Trott, G.E. Tools for the diagnosis of attention-deficit/hyperactivity disorder in adults: Self-rating behaviour questionnaire and diagnostic checklist. Nervenarzt 2004 , 75 , 888–895. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Kooij, J.; Francken, M. Diagnostisch Interview voor ADHD Bij Volwassenen ; DIVA Foundation: Den Haag, The Netherlands, 2010. [ Google Scholar ]
• Paucke, M.; Stark, T.; Exner, C.; Kallweit, C.; Hegerl, U.; Strauß, M. Attention deficit-hyperactivity disorder (ADHD) and comorbid mental disorders: ADHD-specific self-rating scales in differential diagnostics. Nervenarzt 2018 , 89 , 1287–1293. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Luderer, M.; Sick, C.; Kaplan-Wickel, N.; Reinhard, I.; Richter, A.; Kiefer, F.; Weber, T. Prevalence estimates of ADHD in a sample of inpatients with alcohol dependence. J. Atten. Disord. 2020 , 24 , 2072–2083. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Banaschewski, T.; Hohmann, S.; Millenet, D.P.S.; der Kinder, A.A. S3-Leitlinie ADHS bei Kindern, Jugendlichen und Erwachsenen Registernummer 028-045. In 2017: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. ; AWMF: Dewsbury, UK, 2017. [ Google Scholar ]
• Parkin, R.; Mc Nicholas, F.; Hayden, J.C. A systematic review of interventions to enhance adherence and persistence with ADHD pharmacotherapy. J. Psychiatr. Res. 2022 , 152 , 201–218. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• McIntosh, A.; Conlon, L.; Lawrie, S.; Stanfield, A.C. Compliance therapy for schizophrenia. Cochrane Database Syst. Rev. 2006 , 2006 , CD003442. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Salvi, V.; Ribuoli, E.; Servasi, M.; Orsolini, L.; Volpe, U. ADHD and Bipolar Disorder in Adulthood: Clinical and Treatment Implications. Medicina 2021 , 57 , 466. [ Google Scholar ] [ CrossRef ]
• Rosenstein, L.D. ADHD as a Potential Risk Factor in Poor Antiretroviral Adherence Rates in HIV: A Brief Narrative Review and Suggestions for Future Research. Neuropsychol. Rev. 2021 , 31 , 683–688. [ Google Scholar ] [ CrossRef ]

Share and Cite

Gaspar, N.; Kilarski, L.L.; Rosen, H.; Huppertz, M.; Philipsen, A.; Rohner, H. Attention Deficit Hyperactivity Disorder: A Risk Factor for Premature Discontinuation of Inpatient Opioid Withdrawal Treatment. J. Clin. Med. 2024 , 13 , 3301. https://doi.org/10.3390/jcm13113301

Gaspar N, Kilarski LL, Rosen H, Huppertz M, Philipsen A, Rohner H. Attention Deficit Hyperactivity Disorder: A Risk Factor for Premature Discontinuation of Inpatient Opioid Withdrawal Treatment. Journal of Clinical Medicine . 2024; 13(11):3301. https://doi.org/10.3390/jcm13113301

Gaspar, Nikolas, Laura Luisa Kilarski, Helena Rosen, Maximilian Huppertz, Alexandra Philipsen, and Henrik Rohner. 2024. "Attention Deficit Hyperactivity Disorder: A Risk Factor for Premature Discontinuation of Inpatient Opioid Withdrawal Treatment" Journal of Clinical Medicine 13, no. 11: 3301. https://doi.org/10.3390/jcm13113301

Article Metrics

Article access statistics, further information, mdpi initiatives, follow mdpi.

Subscribe to receive issue release notifications and newsletters from MDPI journals